Trial from

For full trial details, please see the original record at

Trial ID
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects
Scientific title
A Two-Part Open-Label, Randomized, Sequential, Crossover, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of C-10355 and C-10358 in Healthy Volunteers, With a PK Comparison to Kalydeco®
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Study type
Description of intervention(s) / exposure
Treatment: drugs - C-10355
Treatment: drugs - C-10358
Treatment: drugs - Kalydeco

Active Comparator: C-10355, 25 mg - single oral dose.

Active Comparator: C-10358, 25 mg - single oral dose.

Active Comparator: C-10355 or C-10358, 75 mg - single oral dose.

Active Comparator: C-10355 or C-10358, 150 mg - single oral dose.

Active Comparator: Kalydeco, 150 mg - single oral dose.

Active Comparator: C-10355 or C-10358, 300 mg - single oral dose.

Treatment: drugs: C-10355

Treatment: drugs: C-10358

Treatment: drugs: Kalydeco

Intervention code [1] 0 0
Treatment: drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Number of Participants with Adverse Events as a Measure of Safety and Tolerability - adverse events categorized by body system and MedDRA term
Timepoint [1] 0 0
24 hours
Primary outcome [2] 0 0
Pharmacokinetic Profile - Measure exposure of test articles using area under the concentration time curve (AUC), maximum concentration (Cmax), half life (T 1/2)
Timepoint [2] 0 0
96 hours

Key inclusion criteria
- Healthy adults between 18 and 50 years of age, inclusive

- Body weight = 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive, at
Minimum age
18 Years
Maximum age
50 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- History of clinically significant central nervous system (eg, seizures), cardiac,
pulmonary, metabolic, renal (including nephrolithiasis), hepatic, including history of
Gilbert's syndrome or gastrointestinal (GI) conditions

- PR interval = 220 msec or QRS duration = 120 msec or QTcF interval > 450 msec obtained
at screening visit or prior to the first dose of study drug

- Liver function tests greater than the upper limit of normal.

- Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
virus surface antigen, or hepatitis C virus antibody at screening

- Urinalysis positive for greater than trace blood, protein or glucose

- A positive screen for alcohol, drugs of abuse, or tobacco use.

- Inability to comply with food and beverage restrictions during study participation.

- Donation or blood collection or acute loss of blood prior to screening.

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
CMAX - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Concert Pharmaceuticals

Ethics approval
Ethics application status

Brief summary
This two-part study will assess, in healthy volunteers, under both fasted and fed conditions,
and in a sequential manner, the safety, tolerability and pharmacokinetics (PK) profile of
single doses of C-10355 and C-10358 and single ascending doses of the selected compound
compared to a single dose of Kalydeco®.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Lana Pilja
Address 0 0
Concert Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries
Contact person responsible for updating information